Peapod Lane Capital LLC Has $4.52 Million Holdings in Alto Neuroscience, Inc. $ANRO

Peapod Lane Capital LLC lowered its stake in Alto Neuroscience, Inc. (NYSE:ANRO) by 9.9% in the 4th quarter, Holdings Channel reports. The firm owned 253,992 shares of the company’s stock after selling 27,971 shares during the quarter. Alto Neuroscience accounts for approximately 3.8% of Peapod Lane Capital LLC’s portfolio, making the stock its 3rd largest position. Peapod Lane Capital LLC’s holdings in Alto Neuroscience were worth $4,521,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also added to or reduced their stakes in the stock. Armistice Capital LLC boosted its stake in Alto Neuroscience by 0.7% in the 3rd quarter. Armistice Capital LLC now owns 1,636,000 shares of the company’s stock worth $6,577,000 after purchasing an additional 12,000 shares during the period. Susquehanna International Group LLP boosted its position in shares of Alto Neuroscience by 154.9% during the 3rd quarter. Susquehanna International Group LLP now owns 155,676 shares of the company’s stock valued at $626,000 after acquiring an additional 94,613 shares during the last quarter. Millennium Management LLC boosted its position in shares of Alto Neuroscience by 4.3% during the 3rd quarter. Millennium Management LLC now owns 315,758 shares of the company’s stock valued at $1,269,000 after acquiring an additional 12,896 shares during the last quarter. Two Sigma Investments LP boosted its position in shares of Alto Neuroscience by 160.6% during the 3rd quarter. Two Sigma Investments LP now owns 116,579 shares of the company’s stock valued at $469,000 after acquiring an additional 71,844 shares during the last quarter. Finally, Bridgeway Capital Management LLC boosted its position in shares of Alto Neuroscience by 43.5% during the 3rd quarter. Bridgeway Capital Management LLC now owns 77,653 shares of the company’s stock valued at $312,000 after acquiring an additional 23,553 shares during the last quarter.

Analysts Set New Price Targets

A number of analysts have recently issued reports on ANRO shares. Robert W. Baird dropped their price target on Alto Neuroscience from $41.00 to $38.00 and set an “outperform” rating for the company in a research report on Thursday, April 2nd. Jefferies Financial Group reiterated a “buy” rating and set a $35.00 price target on shares of Alto Neuroscience in a research report on Monday, March 16th. Wall Street Zen downgraded Alto Neuroscience from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. HC Wainwright reiterated a “buy” rating and set a $50.00 price target on shares of Alto Neuroscience in a research report on Thursday, April 2nd. Finally, Wedbush dropped their price target on Alto Neuroscience from $22.00 to $21.00 and set a “neutral” rating for the company in a research report on Thursday, April 2nd. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Alto Neuroscience presently has an average rating of “Moderate Buy” and a consensus target price of $35.14.

Alto Neuroscience Stock Performance

Shares of ANRO opened at $25.67 on Friday. The stock has a 50-day moving average price of $21.76 and a 200-day moving average price of $16.80. The company has a market cap of $820.16 million, a PE ratio of -11.78 and a beta of 2.01. Alto Neuroscience, Inc. has a 12-month low of $2.12 and a 12-month high of $28.44. The company has a current ratio of 15.69, a quick ratio of 15.69 and a debt-to-equity ratio of 0.12.

Alto Neuroscience (NYSE:ANRO) last released its earnings results on Monday, March 16th. The company reported ($0.45) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.11. As a group, equities analysts forecast that Alto Neuroscience, Inc. will post -2.48 earnings per share for the current fiscal year.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.